Zevra Therapeutics, Inc. (ZVRA) — DEFA14A Filings

DEFA14A Filings (5)

• Zevra Therapeutics Files Proxy Materials — May 21, 2025 Risk: low
  Zevra Therapeutics, Inc. (formerly KemPharm, Inc.) filed a Definitive Additional Materials (DEFA14A) on May 21, 2025. The filing relates to the company's proxy
• Zevra Therapeutics Files Proxy Materials — May 8, 2025 Risk: low
  Zevra Therapeutics, Inc. (formerly KemPharm, Inc.) filed a Definitive Additional Materials (DEFA14A) on May 8, 2025. This filing relates to the company's proxy
• Zevra Therapeutics Files Proxy Materials — Apr 21, 2025 Risk: low
  Zevra Therapeutics, Inc. filed a Definitive Additional Materials (DEFA14A) on April 21, 2025. This filing relates to the company's proxy statement and indicates
• Zevra Therapeutics Files Proxy Statement — Mar 31, 2025 Risk: low
  Zevra Therapeutics, Inc. (formerly KemPharm, Inc.) filed a DEFA14A proxy statement on March 31, 2025. The filing indicates no fee was required for this submissi
• Zevra Therapeutics Files Proxy Materials — Apr 29, 2024 Risk: low
  Zevra Therapeutics, Inc. (formerly KemPharm, Inc.) filed a Definitive Additional Materials proxy statement on April 29, 2024. The filing relates to the company'

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX